Disparities in lipid control and statin drug use among diabetics with noncoronary atherosclerotic vascular disease vs those with coronary artery disease

被引:7
作者
Thapa, Rashmi [1 ]
Sharma, Suresh [1 ]
Jeevanantham, Vinodh [1 ]
Hu, Casper [1 ]
Myers, Taylor [1 ]
Vacek, James L. [1 ]
Dawn, Buddhadeb [1 ]
Gupta, Kamal [1 ]
机构
[1] Univ Kansas Med Ctr & Hosp, Div Cardiovasc Dis, Dept Internal Med, Kansas City, KS 66160 USA
关键词
Diabetes mellitus; Noncoronary atherosclerotic vascular disease; Lipids; Statin; Peripheral arterial disease; Carotid stenosis; Abdominal aortic aneurysm; SCANDINAVIAN-SIMVASTATIN-SURVIVAL; INTERVENTION OUTCOMES NETWORK; ASSOCIATION TASK-FORCE; MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; HEART-ASSOCIATION; CHOLESTEROL LEVELS; SUBGROUP-ANALYSES; RISK; PREVENTION;
D O I
10.1016/j.jacl.2014.11.006
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
BACKGROUND: Diabetes mellitus (DM), coronary artery disease (CAD), and noncoronary atherosclerotic vascular diseases (NCVDs) have similar risks of cardiovascular events and similar recommendations for lipid control. There are limited data regarding lipid control in diabetic patients with NCVD in current clinical practice. OBJECTIVE: To assess current day practice of lipid control in patients with DM with NCVD vs those with CAD. METHODS: We retrospectively identified 3336 patients with DM and known atherosclerotic vascular disease between January 2009 and March 2012. We compared demographic variables, lipid levels, and statin use in diabetics with CAD alone vs diabetics without CAD but with one or more NCVD. RESULTS: There were 234 patients in DM with NCVD group and 3102 patients in DM with CAD group. The DM with NCVD group had a higher mean total cholesterol (152 +/- 40 vs 146 +/- 42 mg/dL; P = .019) and mean low-density lipoprotein (LDL; 86 +/- 35 vs 80 +/- 34 mg/dL; P = .04) with only 70% of patients achieving LDL of <100 mg/dL (compared with 80% in the DM with CAD group; P < .001). Statin use was 100% in CAD vs 75% in NCVD group (P < .001). In addition to limited use of more potent statins in the NCVD group, there was also a significantly lower dose of statins used overall. CONCLUSION: Our study demonstrates lower use and less aggressive application of statins among diabetics with NCVD compared with diabetics with CAD, resulting in higher mean LDL and total cholesterol in the NCVD group. (C) 2015 National Lipid Association. All rights reserved.
引用
收藏
页码:241 / 246
页数:6
相关论文
共 34 条
[1]
American Diabetes Association, 2010, International, V33, pS11, DOI DOI 10.2337/dc10-S011
[2]
Brott TG, 2011, CIRCULATION, V124, pE54, DOI [10.1161/CIR.0b013e31820d8c98, 10.1161/CIR.0b0113e31820d8c98]
[3]
Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: The Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry®-Get With The Guidelines (GWTG)™ acute myocardial infarction mortality model and risk score [J].
Chin, Chee Tang ;
Chen, Anita Y. ;
Wang, Tracy Y. ;
Alexander, Karen P. ;
Mathews, Robin ;
Rumsfeld, John S. ;
Cannon, Christopher P. ;
Fonarow, Gregg C. ;
Peterson, Eric D. ;
Roe, Matthew T. .
AMERICAN HEART JOURNAL, 2011, 161 (01) :113-122.e2
[4]
Collins R, 2003, LANCET, V361, P2005
[5]
Statin therapy is associated with improved survival after endovascular and open aneurysm repair [J].
de Bruin, Jorg L. ;
Baas, Annette F. ;
Heymans, Martijn W. ;
Buimer, Mathijs G. ;
Prinssen, Monique ;
Grobbee, Diederick E. ;
Blankensteijn, Jan D. .
JOURNAL OF VASCULAR SURGERY, 2014, 59 (01) :39-U89
[6]
Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels -: Subgroup analyses in the cholesterol and recurrent events (CARE) trial [J].
Goldberg, RB ;
Mellies, MJ ;
Sacks, FM ;
Moyé, LA ;
Howard, BV ;
Howard, WJ ;
Davis, BR ;
Cole, TG ;
Pfeffer, MA ;
Braunwald, E .
CIRCULATION, 1998, 98 (23) :2513-2519
[7]
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421
[8]
Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels -: Subgroup analyses in the Scandinavian simvastatin survival study [J].
Haffner, SM ;
Alexander, CM ;
Cook, TJ ;
Boccuzzi, SJ ;
Musliner, TA ;
Pedersen, TR ;
Kjekshus, J ;
Pyörälä, K .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (22) :2661-2667
[9]
Centralized Pan-european Survey on the Undertreatment of Hypercholesterolaemia (CEPHEUS) [J].
Hermans, Michel P. ;
Van Mieghem, Walter ;
Vandenhoven, Guy ;
Vissers, Eugene .
ACTA CARDIOLOGICA, 2009, 64 (02) :177-185
[10]
ILLINGWORTH DR, 1994, CLIN THER, V16, P366